ArticleBMC infectious diseases2025
Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with malignancies: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio as prognostic indicators inFrontiers in medicine · 2026Article
- A Rare Case of Concurrent Tropheryma Whipplei and Pneumocystis Jirovecii Pneumonia in a Patient During Endocrine Therapy for Breast Cancer.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPneumocystis jirovecii pneumonia (PJP) is a fatal opportunistic infectious disease. We conducted this study to describe the clinical characteristics and explore the prognostic factors of patients with concurrent malignancies and PJP (malignancy-PJP).
methodsWe retrospectively enrolled consecutive patients with malignancies diagnosed with PJP in our center from January 2014 to December 2022. The participants were classified into a hematological malignancy group and a non-hematological malignancy group. Cox regression models were used to analyze prognostic factors.
resultsFifty-six malignancy-PJP patients were enrolled in our study with an average age of 63 (52, 68) years, 60.7% of whom were males. There were 33 (58.9%) hematological malignancy patients and 23 (41.1%) non-hematological malignancy patients. Overall, 29 (51.8%) patients died. Compared with the non-hematological malignancy group, more patients received mechanical ventilation (p = 0.03) in the hematological malignancy group. Moreover, shorter periods from the onset of underlying malignancies (p < 0.01) and from the first dosage of chemotherapy (p = 0.04) to PJP infection were significantly more common in patients with hematological malignancies. However, patients with non-hematological malignancies presented more pleural thickening (p = 0.03) on chest computed tomography (CT). Multivariate analysis revealed that non-solid malignancies (HR = 2.77, p = 0.03, 95% CI: 1.12-6.89), cytomegalovirus (CMV) viremia (HR = 3.33, p < 0.01, 95% CI: 1.51-7.33), bacterial hospital-acquired pneumonia (HAP) (HR = 2.21, p = 0.04, 95% CI: 1.03-4.77), and pneumomediastinum (HR = 2.50, p < 0.05, 95% CI: 1.01-6.14) were independent risk factors for survival in malignancy-PJP patients.
conclusionsCompared with patients with non-hematological malignancies, patients with hematological malignancies were more likely to require mechanical ventilation and to be infected with PJP within a shorter time from the onset of underlying malignancies and from the first chemotherapy treatment. Non-solid malignancies, CMV viremia, bacterial HAP, and pneumomediastinum were independent risk factors for survival in patients with malignancy-PJP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.